Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis.
Aktas O, Ziemssen F, Ziemssen T, Klistorner A, Butzkueven H, Izquierdo G, Leocani L, Balcer LJ, Galetta SL, Castrillo-Viguera C, Bradley DP, Naylor ML, Belachew S, Franchimont N, Zhu B, Cheng W; RENEWED Investigators. Aktas O, et al. Among authors: castrillo viguera c. Mult Scler Relat Disord. 2024 Nov 24;93:106185. doi: 10.1016/j.msard.2024.106185. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 39662163 Free article.
Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
Newsome SD, Mokliatchouk O, Castrillo-Viguera C, Naylor ML. Newsome SD, et al. Among authors: castrillo viguera c. Mult Scler Relat Disord. 2020 May;40:101954. doi: 10.1016/j.msard.2020.101954. Epub 2020 Jan 17. Mult Scler Relat Disord. 2020. PMID: 32078948 Free article. Clinical Trial.
Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study.
Strzok S, Cleanthous S, Pompilus F, Cano SJ, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY. Strzok S, et al. Among authors: castrillo viguera c. Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783766. doi: 10.1177/2055217318783766. eCollection 2018 Apr-Jun. Mult Scler J Exp Transl Clin. 2018. PMID: 30090638 Free PMC article.
Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Chen T, O'Gorman J, Castrillo-Viguera C, Rajagovindan R, Curiale GG, Tian Y, Patel D, von Rosenstiel P, von Hehn C, Salloway S, Hock C, Nitsch RM, Haeberlein SB, Sandrock A, Singhal P. Chen T, et al. Among authors: castrillo viguera c. Alzheimers Dement. 2024 May;20(5):3406-3415. doi: 10.1002/alz.13755. Epub 2024 Apr 3. Alzheimers Dement. 2024. PMID: 38567735 Free PMC article. Clinical Trial.
Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study.
Cleanthous S, Strzok S, Pompilus F, Cano S, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY. Cleanthous S, et al. Mult Scler J Exp Transl Clin. 2018 May 17;4(2):2055217318776990. doi: 10.1177/2055217318776990. eCollection 2018 Apr-Jun. Mult Scler J Exp Transl Clin. 2018. PMID: 29796290 Free PMC article.
16 results